<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2014.3029</article-id>
<article-id pub-id-type="publisher-id">or-31-04-1961</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>MING</given-names></name><xref rid="af1-or-31-04-1961" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>QIAN</given-names></name><xref rid="af2-or-31-04-1961" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>WU</surname><given-names>LIANG</given-names></name><xref rid="af3-or-31-04-1961" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>JIA</surname><given-names>CHENGYOU</given-names></name><xref rid="af4-or-31-04-1961" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author">
<name><surname>SHI</surname><given-names>FUHUA</given-names></name><xref rid="af5-or-31-04-1961" ref-type="aff">5</xref></contrib>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>SHAOCAI</given-names></name><xref rid="af6-or-31-04-1961" ref-type="aff">6</xref></contrib>
<contrib contrib-type="author">
<name><surname>PENG</surname><given-names>AIMEI</given-names></name><xref rid="af1-or-31-04-1961" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>GUOLIANG</given-names></name><xref rid="af1-or-31-04-1961" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>SONG</surname><given-names>XIAOLIAN</given-names></name><xref rid="af1-or-31-04-1961" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>CHANGHUI</given-names></name><xref rid="af1-or-31-04-1961" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-or-31-04-1961"/></contrib></contrib-group>
<aff id="af1-or-31-04-1961">
<label>1</label>Department of Respiratory Medicine, Shanghai 10th People&#x02019;s Hospital, Tongji University, Shanghai 200072, P.R. China</aff>
<aff id="af2-or-31-04-1961">
<label>2</label>Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200032, P.R. China</aff>
<aff id="af3-or-31-04-1961">
<label>3</label>Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, P.R. China</aff>
<aff id="af4-or-31-04-1961">
<label>4</label>Department of Nuclear Medicine, Shanghai 10th People&#x02019;s Hospital, Tongji University, Shanghai 200072, P.R. China</aff>
<aff id="af5-or-31-04-1961">
<label>5</label>Department of Neural Medicine, People&#x02019;s Hospital of Zunhua County, Tangshan, Hebei 064200, P.R. China</aff>
<aff id="af6-or-31-04-1961">
<label>6</label>Department of Cardiology, People&#x02019;s Hospital of Zunhua County, Tangshan, Hebei 064200, P.R. China</aff>
<author-notes>
<corresp id="c1-or-31-04-1961">Correspondence to: Dr Changhui Wang, Department of Respiratory Medicine, Shanghai 10th People&#x02019;s Hospital, Tongji University, Shanghai 200072, P.R. China, E-mail: <email>wang-changhui@hotmail.com</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>4</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>02</month>
<year>2014</year></pub-date>
<volume>31</volume>
<issue>4</issue>
<fpage>1961</fpage>
<lpage>1967</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>12</month>
<year>2013</year></date>
<date date-type="accepted">
<day>27</day>
<month>01</month>
<year>2014</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>The aim of the present study was to determine whether serum miR-499 may be used as a biomarker for early detection of non-small cell lung cancer (NSCLC). The present study was designed as an initial screening phase and a subsequent validation phase. In the screening phase, we analyzed serum levels of miR-499 in a subset of 40 patients with stage I (n&#x0003D;20) and stage IV (n&#x0003D;20) NSCLC. In the validation phase, miR-499 expression levels in serum (n&#x0003D;514) and tissue (n&#x0003D;136) from NSCLC patients were detected in a large and independent cohort of 514 patients. miR-499 in the screening phase was found to be significantly elevated in the serum of stage I NSCLC patients compared with that in stage IV NSCLC patients (P&lt;0.001). Validation analysis showed that serum miR-499 levels were robust in differentiating NSCLC patients from control subjects &#x0005B;area under the curve (AUC)&#x0003D;0.906; 95&#x00025; confidence interval (CI)&#x0003D;0.879 to 0.929). Serum miR-499 levels were significantly lower in stage III and IV patients compared with those with stage I (both P&lt;0.001) or II (both P&lt;0.001). Low serum miR-499 levels were associated with shorter overall survival and served as an independent prognostic biomarker in NSCLC patients &#x0005B;hazard ratio (HR)&#x0003D;1.63; 95&#x00025; CI&#x0003D;1.33&#x02013;2.0; P&lt;0.0001). In addition, low serum levels of miR-499 indicated a poor disease-free survival in stage I&#x02013;II NSCLC patients. Serum miR-499 may prove to be a promising biomarker for early detection and prognosis prediction of NSCLC.</p></abstract>
<kwd-group>
<kwd>lung cancer</kwd>
<kwd>microRNA</kwd>
<kwd>non-invasive biomarker</kwd>
<kwd>early diagnosis</kwd>
<kwd>prognostic marker</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Lung cancer is the leading cause of cancer-related mortality in both men and women, resulting in ~221,130 new cases and 156,940 deaths in the United States in 2011 (<xref rid="b1-or-31-04-1961" ref-type="bibr">1</xref>). Non-small cell lung cancer (NSCLC) represents 85&#x00025; of all lung cancer cases, and most NSCLC patients present with advanced disease with a very poor rate of cure (<xref rid="b2-or-31-04-1961" ref-type="bibr">2</xref>,<xref rid="b3-or-31-04-1961" ref-type="bibr">3</xref>). Since the 5-year survival of patients with metastatic NSCLC is &lt;15&#x00025;, prognostic assessment of the patient is essential for the choice of better therapeutic strategies. The current challenge demands the discovery of accurate and non-invasive biomarkers for diagnosis, prognosis and prediction of recurrence to improve the clinical management of NSCLC patients.</p>
<p>During the past decades, several screening tests, including CT scan and bronchoscopy, have been used for early detection of lung cancer (<xref rid="b4-or-31-04-1961" ref-type="bibr">4</xref>). However, compliance with these screening tests has been far from adequate. An ideal screening method should have a high sensitivity and specificity for lung cancer. Currently, one of the most important prognostic factors in NSCLC is the anatomical extent of disease, as described by the tumor node metastasis (TNM) classification (<xref rid="b5-or-31-04-1961" ref-type="bibr">5</xref>). However, it fails to consider the variety of NSCLC patients, tumor and environmental factors that influence prognosis, and a large variability in disease outcomes that has been observed in subsets of patients with the same clinical features (<xref rid="b6-or-31-04-1961" ref-type="bibr">6</xref>). Therefore, there is a clear need to identify biomarkers for the early detection of NSCLC, and to categorize different prognostic groups and improve the clinical management of NSCLC patients.</p>
<p>MicroRNAs (miRNAs) are non-coding RNA molecules of ~21&#x02013;23 nucleotides in length that play an important role in regulation of mRNA expression (<xref rid="b7-or-31-04-1961" ref-type="bibr">7</xref>). miRNAs are known to be involved in various cellular processes and are associated with various diseases including cancer (<xref rid="b8-or-31-04-1961" ref-type="bibr">8</xref>,<xref rid="b9-or-31-04-1961" ref-type="bibr">9</xref>). Several studies have demonstrated that miRNAs play important roles in the initiation and progression of cancer. In addition, miRNA expression profiles and specific miRNAs have been shown to be potential diagnostic or prognostic tools for cancer (<xref rid="b10-or-31-04-1961" ref-type="bibr">10</xref>&#x02013;<xref rid="b12-or-31-04-1961" ref-type="bibr">12</xref>).</p>
<p>Recent studies (<xref rid="b13-or-31-04-1961" ref-type="bibr">13</xref>,<xref rid="b14-or-31-04-1961" ref-type="bibr">14</xref>) have also shown that circulating miRNAs may constitute accurate methods for diagnosis and prognosis of NSCLC. A study by Markou <italic>et al</italic> (<xref rid="b15-or-31-04-1961" ref-type="bibr">15</xref>) demonstrated that high expression of serum miR-21 and miR-30e-5p was associated with shorter overall survival (OS). Hu <italic>et al</italic> (<xref rid="b14-or-31-04-1961" ref-type="bibr">14</xref>) also reported a 4-miRNA signature (miR-486, miR-30d, miR-1 and miR-499) that predicted survival of stage I&#x02013;IIIa NSCLC. However, whether the expression profile of circulating miR-499 reflects the miRNA profile of tumor tissue remains unclear. In addition, the relationship between dysregulated miRNAs and tumor stage is also uncertain. In the present study, we evaluated the possible association of miR-499 with early detection of NSCLC and survival of NSCLC patients in an attempt to further clarify the impact of miRNAs on the diagnosis and prognosis of lung cancer.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Study design</title>
<p>The present study was approved by the institutional review board of Shanghai Pulmonary Disease Hospital. All participants provided written consent and indicated willingness to donate their blood and tissue samples for research. A total of 568 subjects were enrolled in this study, including 514 NSCLC patients and 54 age- and gender-matched healthy volunteers as controls. NSCLC patients were recruited at Shanghai Pulmonary Disease Hospital affiliated to Tongji University in Shanghai, China, between January 2007 and December 2011. Patients were excluded if they had any of the following: self-reported previous cancer history, metastasis from other organs, or if they underwent chemotherapy or radiotherapy before blood collection. They were followed-up at 3-month intervals by telephone after the first visit to the hospital.</p>
<p>The present study was designed as an initial screening phase and a subsequent validation phase. In the screening phase, serum levels of miR-499 (<xref rid="b14-or-31-04-1961" ref-type="bibr">14</xref>,<xref rid="b16-or-31-04-1961" ref-type="bibr">16</xref>) were analyzed in a subset of 40 patients with stage I (n&#x0003D;20) and stage IV (n&#x0003D;20) NSCLC. To further assess the specificity of miRNA expression, serum samples were collected from 12 patients with NSCLC and 12 gender- and age-matched normal controls. In the validation phase, miR-499 expression levels in serum (n&#x0003D;514) and tissues (n&#x0003D;136) from NSCLC patients were evaluated in a large and independent cohort of 514 patients.</p></sec>
<sec>
<title>RNA isolation and qRT-PCR from serum and tissues</title>
<p>miRNAs were extracted from blood samples using the Qiagen miRNeasy kit (Qiagen, Valencia, CA, USA). Briefly, 250 &#x003BC;l serum was centrifuged at 10,000 rpm for 10 min at 4&#x000B0;C. miRNAs were enriched and purified according to the manufacturer&#x02019;s protocol. To allow for normalization of sample-to-sample variation in the RNA isolation step, synthetic <italic>C. elegans</italic> miRNA (cel-miR-39) was added to each sample (<xref rid="b12-or-31-04-1961" ref-type="bibr">12</xref>,<xref rid="b17-or-31-04-1961" ref-type="bibr">17</xref>).</p>
<p>MiRNAs were extracted from fresh frozen tissue samples using PureLink&#x02122; miRNA Isolation kit (Life Technologies Corporation, Carlsbad, CA, USA). Briefly, fresh frozen tissue samples were microdissected to enrich for neoplastic cells. Homogenized samples were centrifuged, followed by deparaffinization and RNA extraction using the manufacturer&#x02019;s protocol.</p>
<p>PCR reactions for quantifying miR-499, miR-39 and miR-16 were performed in triplicate using the TaqMan microRNA Reverse Transcription kit (Applied Biosystems, USA). qRT-PCR was performed in an ABI Prism 7000 sequence detection system (Applied Biosystems) according to the manufacturer&#x02019;s instructions, with the following cycling conditions: 95&#x000B0;C for 10 min, followed by 40 cycles at 95&#x000B0;C for 15 sec and 60&#x000B0;C for 1 min.</p></sec>
<sec>
<title>Calculation of miRNA expression</title>
<p>Relative quantification of miR-499 expression was calculated with the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method (<xref rid="b18-or-31-04-1961" ref-type="bibr">18</xref>) &#x0005B;Applied Biosystems; User Bulletin no. 2 (P/N 4303859)&#x0005D; and normalized using cel-miR-39 (for serum samples) and miR-16 (<xref rid="b19-or-31-04-1961" ref-type="bibr">19</xref>) (for tissue samples) using the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method, knowing that it facilitates detecting and quantifies exclusively mature miRNAs but not their precursors.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Mann-Whitney U and Kruskal-Wallis analyses of variance were used to evaluate statistical differences in serum or tissue miRNA expression between unpaired groups and multiple comparison groups. &#x003C7;<sup>2</sup> test was used for categorical data. A multivariable logistic regression model was used to calculate odds ratios (ORs) for patients associated with NSCLC according to serum miRNA levels.</p>
<p>Disease-free survival (DFS) and OS were measured for each patient. Survival curves were estimated using the Kaplan-Meier method, and differences between them were evaluated by the log-rank test. Cox proportional hazard regression test was used to estimate univariate and multivariate hazard ratios for recurrence and prognosis with a step-down method.</p>
<p>Receiver operating characteristic (ROC) curves were established for discriminating NSCLC and controls. The optimal miRNA expression cut-off threshold values were determined at the point on the ROC curve at which Youden&#x02019;s index (<xref rid="b20-or-31-04-1961" ref-type="bibr">20</xref>) was maximal.</p>
<p>All P-values are two-sided and P&lt;0.05 was considered to indicate a statistically significant difference. All statistical analyses were carried out using MedCalc version 11.2 (Mariakerke, Belgium).</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Serum and tissue miR-499 expression during the screening phase</title>
<p>In the screening phase, we investigated the relative expression levels of the miR-499 in a subset of serum specimens from 20 NSCLC patients with stage IV compared with 20 patients with stage I. It was found that miR-499 was significantly elevated in the serum of NSCLC patients with stage I compared with stage IV (P&lt;0.001; <xref rid="f1-or-31-04-1961" ref-type="fig">Fig. 1A</xref>). We next examined the feasibility of detecting the expression of serum miR-499 in 12 NSCLC patients and 12 healthy control subjects. It was found that serum miR-499 levels were significantly decreased in the sera of NSCLC patients (P&lt;0.001; <xref rid="f1-or-31-04-1961" ref-type="fig">Fig. 1B</xref>). Expression of miR-499 was determined in a small set of 12 NSCLCs compared with the adjacent normal tissue. miR-499 level was also found to be reduced in NSCLC tissues compared with normal tissues (P&lt;0.001; <xref rid="f1-or-31-04-1961" ref-type="fig">Fig. 1C</xref>). These results indicated that serum miR-499 was downregulated in NSCLC patients compared with adjacent tissues.</p>
<p>Based on these observations, we focused the rest of our study on miR-499 for further assessment of its efficacy as a diagnostic, prognostic and recurrence predictive biomarker in NSCLC patients.</p></sec>
<sec>
<title>Serum miR-499c expression level as a diagnostic biomarker in NSCLC patients</title>
<p>To examine whether miR-499 had diagnostic potential, 568 serum samples, including 514 from NSCLC patients and 54 from normal controls, were analyzed. It was found that miR-499 expression levels were downregulated markedly in sera of NSCLC patients as compared with those in normal controls (P&lt;0.001; <xref rid="f2-or-31-04-1961" ref-type="fig">Fig. 2A</xref>). In addition, when all NSCLC patients were grouped based on TNM stage, miR-499 expression levels were significantly lower in stage III and IV patients than those in stage I or II patients (both P&lt;001, <xref rid="f2-or-31-04-1961" ref-type="fig">Fig. 2A</xref>). The potential clinical significance of serum miR-499 expression is presented in <xref rid="tI-or-31-04-1961" ref-type="table">Table I</xref>.</p>
<p>Next, we determined whether miR-499 possessed any significance in sensitivity and specificity in lung cancer patients. ROC curves were analyzed, indicating that serum miR-499 levels were robust in differentiating patients with NSCLC from control subjects with an area under the ROC curve (AUC) value of 0.906 (95&#x00025; CI&#x0003D;0.879 to 0.929) (<xref rid="f2-or-31-04-1961" ref-type="fig">Fig. 2B</xref>). At the cut-off value of 1.330 for miR-499, the optimal sensitivity and specificity were 73.7 and 92.7&#x00025;, respectively. Multivariate logistic regression analyses on variables including age, gender and serum miRNAs showed that miR-499 was a potential biomarker for NSCLC diagnosis (P&lt;0.0001). The OR for patients with miR-499 &lt;1.0247 associated with NSCLC was 64.1 (95&#x00025; CI: 20.83&#x02013;197.49). These results indicated that serum miR-499 had potential significance with respect to the sensitivity and specificity in the diagnosis of NSCLC.</p></sec>
<sec>
<title>Correlation between serum/tissue miR-499 expression and survival of NSCLC patients</title>
<p>Based on the above findings, we further evaluated whether serum miR-499 levels may predict the prognosis of NSCLC patients. As anticipated, OS was poorer in patients with lower serum levels of miR-499 (P&#x0003D;0.005, log-rank test; <xref rid="f3-or-31-04-1961" ref-type="fig">Fig. 3A</xref>). In addition, lower serum levels of miR-499 also predicted poorer survival in patients with stage I&#x02013;II and III&#x02013;IV NSCLC (P&#x0003D;0.0012 and &lt;0.0001, log-rank test; <xref rid="f3-or-31-04-1961" ref-type="fig">Fig. 3B and C</xref>). However, tissue miR-499 levels were not significantly associated with survival in NSCLC patients (P&#x0003D;0.3139, log-rank test; <xref rid="f3-or-31-04-1961" ref-type="fig">Fig. 3D</xref>) (<xref rid="tII-or-31-04-1961" ref-type="table">Table II</xref>). Furthermore, the Cox proportional hazard regression model was used to clarify whether serum miR-499 expression was an independent risk factor for prognosis. The result of univariate analysis showed that poor prognosis in NSCLC patients was significantly associated with low serum miR-499 levels but not with tissue miR-499 levels (P&#x0003D;0.0005 and P&#x0003D;0.3139, respectively), high T stage (T3/4, P&lt;0.0001), lymph node metastasis (N1/2/3, P&lt;0.0001), distant metastasis (M1, P&lt;0.0001), and high TNM stage (III/IV, P&lt;0.0001) (<xref rid="tII-or-31-04-1961" ref-type="table">Table II</xref>). The result of multivariate analysis showed that downregulation of serum miR-499 expression was an independent prognostic marker for predicting poorer OS in NSCLC patients (HR&#x0003D;1.63, 95&#x00025; CI&#x0003D;1.33&#x02013;2.0, P&lt;0.0001; <xref rid="tII-or-31-04-1961" ref-type="table">Table II</xref>). These results indicated that downregulation of serum miR-499 expression was an independent prognostic marker for predicting poorer OS in NSCLC patients.</p></sec>
<sec>
<title>Serum miR-499 as a predictive biomarker of tumor recurrence in NSCLC</title>
<p>Next, we analyzed DFS. Patients with low serum miR-499 in stage I&#x02013;II had shorter DFS (P&#x0003D;0.045, log-rank test). To further evaluate whether serum miR-499 levels may be used as a predictor of tumor recurrence after surgery (stage I&#x02013;II), the Cox proportional hazard regression model was performed (<xref rid="tIII-or-31-04-1961" ref-type="table">Table III</xref>). The result of univariate analysis showed that poor DFS was significantly associated with low serum levels of miR-499 (P&#x0003D;0.0304), high TNM stage (II, P&lt;0.0001), and no chemotherapy or radiotherapy (P&lt;0.0001). The result of multivariate analysis showed that low serum miR-499 expression was an independent predictor for tumor recurrence in patients with stage I&#x02013;II NSCLC (HR&#x0003D;1.96, 95&#x00025; CI&#x0003D;1.03&#x02013;3.73, P&#x0003D;0.04). These results indicated that serum miR-499 levels may serve not only as a diagnostic and prognostic marker, but also as a predictor of early recurrence of NSCLC as well.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In the present study, we investigated the potential clinical utility of serum miR-499 and found that serum miR-499 could serve as a non-invasive biomarker for the diagnosis and prediction of prognosis and tumor recurrence in NSCLC patients. The miR-499 levels in serum samples from NSCLC patients were significantly lower than those in healthy controls. miR-499 had a significant diagnostic value for NSCLC and yielded AUC of 0.906 with 73.7&#x00025; sensitivity and 92.7&#x00025; specificity in discriminating NSCLC from normal controls. In addition, the OR for case subjects with low levels of miR-499 expression associated with NSCLC was 64.1 (95&#x00025; CI; 20.83&#x02013;197.49), indicating that miR-499 expression may be exploited as a promising non-invasive biomarker for early detection of NSCLC.</p>
<p>Our study also strongly suggested that serum miR-499 expression may serve as a prognostic biomarker for NSCLC. We found that serum miR-499 levels were significantly lower in patients with stage III or IV NSCLC than those in stage I or II NSCLC. In addition, low serum miR-499 levels (rather than tissue) were associated with shorter OS and may prove to be an independent prognostic biomarker in NSCLC patients. In addition, low serum levels of miR-499 expression indicate a poor DFS in stage I&#x02013;II NSCLC. The multivariable Cox proportional hazards model showed that low serum miR-499 expression was an independent predictor of tumor recurrence in patients with stage I&#x02013;II NSCLC.</p>
<p>To the best of our knowledge, this is the first report to demonstrate the potential role of serum miR-499 in the early detection of NSCLC. Although the observation of the prognostic value of miR-499 is similar to a previous report (<xref rid="b14-or-31-04-1961" ref-type="bibr">14</xref>), our results are the first to demonstrate that low serum miR-499 expression is associated with advanced TNM stage and poor DFS.</p>
<p>Several studies (<xref rid="b21-or-31-04-1961" ref-type="bibr">21</xref>,<xref rid="b22-or-31-04-1961" ref-type="bibr">22</xref>) have reported that miRNAs are potential diagnostic biomarkers and prognostic factors in lung cancer. In 2004, lung tumor-derived miRNAs were first described in tissue by Takamizawa <italic>et al</italic> (<xref rid="b23-or-31-04-1961" ref-type="bibr">23</xref>), who reported that reduced let-7 expression was significantly associated with shortened postoperative survival. A study by Yanaihara <italic>et al</italic> (<xref rid="b21-or-31-04-1961" ref-type="bibr">21</xref>) showed that the tissue miRNA expression profile was a diagnostic and prognostic marker of lung cancer. Serum miRNAs are resistant to RNase digestion, suggesting that miRNAs in serum are sufficiently stable to serve as a clinical biomarker (<xref rid="b12-or-31-04-1961" ref-type="bibr">12</xref>). miR-21 was the first serum miRNA biomarker discovered by Lawrie <italic>et al</italic> (<xref rid="b24-or-31-04-1961" ref-type="bibr">24</xref>), who reported that high serum levels of miR-21 in patients with diffuse large B cell lymphoma were associated with increased relapse-free survival. Chen <italic>et al</italic> (<xref rid="b9-or-31-04-1961" ref-type="bibr">9</xref>) also demonstrated that serum let-7 level was increased in lung cancer patients as compared with healthy controls. In addition, serum miRNAs are prognostic factors for lung cancer. Hu <italic>et al</italic> (<xref rid="b14-or-31-04-1961" ref-type="bibr">14</xref>) found that serum levels of 4 miRNAs (miR-486, miR-30d, miR-1 and miR-499) were significantly associated with OS of NSCLC patients. Boeri <italic>et al</italic> (<xref rid="b25-or-31-04-1961" ref-type="bibr">25</xref>) described plasma miRNA signatures for high risk of lung cancer, diagnosis and prognosis. These findings indicate that circulating miRNAs may be non-invasive diagnostic or prognostic markers for lung cancer.</p>
<p>Previous studies usually focused on the association between miR-499 and the muscle and heart. Wang <italic>et al</italic> (<xref rid="b26-or-31-04-1961" ref-type="bibr">26</xref>) detected the presence of plasma miR-499 in patients with acute myocardial infarction with very low abundance, suggesting it may be a biomarker for early detection of myocardial injury. Donaldson <italic>et al</italic> (<xref rid="b27-or-31-04-1961" ref-type="bibr">27</xref>) found that miR-499 was elevated in the plasma of COPD patients as compared with controls. Recently, Vinci <italic>et al</italic> (<xref rid="b16-or-31-04-1961" ref-type="bibr">16</xref>) found that the expression of miR-499 in NSCLC tissues tended to be lower than controls but the reduction was not statistically significant (P&#x0003D;0.123). However, they found that increased expression of miR-499 was associated high tumor grade. Hu <italic>et al</italic> (<xref rid="b14-or-31-04-1961" ref-type="bibr">14</xref>) showed that low serum levels of miR-499 were significantly associated with short OS. Therefore, the clinical significance of circulating miR-499 levels in NSCLC remains unclear.</p>
<p>The present study demonstrated that the relative expression of serum miR-499 was significantly different between NSCLC patients and normal controls, suggesting that serum miR-499 level may be a useful biomarker for the clinical diagnosis of NSCLC. Screening for lung cancer has long been of interest, with the hope of reducing the number of patients diagnosed with advanced disease. Although screening with low-dose computed tomography (LDCT) has substantially reduced the risk of mortality due to lung cancer, there is a significant chance of a false-positive result (<xref rid="b28-or-31-04-1961" ref-type="bibr">28</xref>,<xref rid="b29-or-31-04-1961" ref-type="bibr">29</xref>). Therefore, serum miR-499 level with high specificity for early detection of NSCLC may be a powerful adjunct to LDCT. Our study showed that preoperative serum miR-499 expression was an independent factor for detecting early tumor recurrence in patients with stage I&#x02013;II NSCLC. In clinical practice, these patients can significantly benefit from timely clinical intervention, thus improving cancer survival. Our data also support the use of miR-499 as a non-invasive biomarker that can facilitate disease risk assessment, severity and survival time in NSCLC patients.</p>
<p>Although our study suggests that miR-499 is a promising screening and assessment tool for NSCLC, there are potential limitations in using miR-499 as a diagnostic, prognostic and recurrence predictive biomarker. Firstly, as no consensus internal controls for circulating miRNA have been established, we used the ideal approach to normalize experimental miRNA data using spiked-in synthetic, non-human mature miRNA from <italic>Caenorhabditis elegans</italic>. Although cel-miR-39 had given consistent expression across all patients and controls, and the method of quantifying relative expression of serum miRNAs was widely recognized, absolute quantization of serum miR-499 expression may further improve the translation of these data into clinical application. Secondly, although selection criteria for lung cancer screening were uncertain, it is unclear whether high-risk people benefit from serum miRNAs tests. Plasma miRNA tests may be more functional for non-invasive diagnosis of lung cancer in individuals with solitary pulmonary nodules (<xref rid="b30-or-31-04-1961" ref-type="bibr">30</xref>,<xref rid="b31-or-31-04-1961" ref-type="bibr">31</xref>). Thirdly, as serum expression of miR-499 has been described in other diseases including COPD and AMI, it may be difficult to differentiate whether serum miR-499 expression is specifically associated with NSCLC. Finally, it is difficult to ensure that the control subjects are healthy, and our clinical materials are solely from Chinese people. A large sample size including diverse ethnic populations may be helpful to eliminate potential sampling error.</p>
<p>In conclusion, serum miR-499 appears to be a novel diagnostic, prognostic and predictive biomarker in patients with NSCLC. Nevertheless, large prospective studies are required to further evaluate our theory before serum miR-499 can be incorporated into routine clinical practice.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by the National Natural Science Foundation of China (81172229, 81372175) and the China Postdoctoral Science Foundation (First Class, 2013M530212).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-or-31-04-1961"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Brawley</surname><given-names>O</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths</article-title><source>CA Cancer J Clin</source><volume>61</volume><fpage>212</fpage><lpage>236</lpage><year>2011</year></element-citation></ref>
<ref id="b2-or-31-04-1961"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>Global cancer statistics in the year 2000</article-title><source>Lancet Oncol</source><volume>2</volume><fpage>533</fpage><lpage>543</lpage><year>2001</year></element-citation></ref>
<ref id="b3-or-31-04-1961"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials</article-title><source>PLoS One</source><volume>7</volume><fpage>e37229</fpage><year>2012</year></element-citation></ref>
<ref id="b4-or-31-04-1961"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name><name><surname>Cokkinides</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening</article-title><source>CA Cancer J Clin</source><volume>63</volume><fpage>88</fpage><lpage>105</lpage><year>2013</year></element-citation></ref>
<ref id="b5-or-31-04-1961"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstraw</surname><given-names>P</given-names></name><name><surname>Ball</surname><given-names>D</given-names></name><name><surname>Jett</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Non-small-cell lung cancer</article-title><source>Lancet</source><volume>378</volume><fpage>1727</fpage><lpage>1740</lpage><year>2011</year></element-citation></ref>
<ref id="b6-or-31-04-1961"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rami-Porta</surname><given-names>R</given-names></name><name><surname>Goldstraw</surname><given-names>P</given-names></name></person-group><article-title>Strength and weakness of the new TNM classification for lung cancer</article-title><source>Eur Respir J</source><volume>36</volume><fpage>237</fpage><lpage>239</lpage><year>2010</year></element-citation></ref>
<ref id="b7-or-31-04-1961"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipowicz</surname><given-names>W</given-names></name><name><surname>Bhattacharyya</surname><given-names>SN</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><article-title>Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?</article-title><source>Nat Rev Genet</source><volume>9</volume><fpage>102</fpage><lpage>114</lpage><year>2008</year></element-citation></ref>
<ref id="b8-or-31-04-1961"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kouwenhove</surname><given-names>M</given-names></name><name><surname>Kedde</surname><given-names>M</given-names></name><name><surname>Agami</surname><given-names>R</given-names></name></person-group><article-title>MicroRNA regulation by RNA-binding proteins and its implications for cancer</article-title><source>Nat Rev Cancer</source><volume>11</volume><fpage>644</fpage><lpage>656</lpage><year>2011</year></element-citation></ref>
<ref id="b9-or-31-04-1961"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ba</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><etal/></person-group><article-title>Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases</article-title><source>Cell Res</source><volume>18</volume><fpage>997</fpage><lpage>1006</lpage><year>2008</year></element-citation></ref>
<ref id="b10-or-31-04-1961"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>YW</given-names></name><name><surname>Ferland-McCollough</surname><given-names>D</given-names></name><name><surname>Jackson</surname><given-names>TJ</given-names></name><name><surname>Bushell</surname><given-names>M</given-names></name></person-group><article-title>microRNAs in cancer management</article-title><source>Lancet Oncol</source><volume>13</volume><fpage>e249</fpage><lpage>e258</lpage><year>2012</year></element-citation></ref>
<ref id="b11-or-31-04-1961"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Miska</surname><given-names>EA</given-names></name><etal/></person-group><article-title>MicroRNA expression profiles classify human cancers</article-title><source>Nature</source><volume>435</volume><fpage>834</fpage><lpage>838</lpage><year>2005</year></element-citation></ref>
<ref id="b12-or-31-04-1961"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Parkin</surname><given-names>RK</given-names></name><name><surname>Kroh</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Circulating microRNAs as stable blood-based markers for cancer detection</article-title><source>Proc Natl Acad Sci USA</source><volume>105</volume><fpage>10513</fpage><lpage>10518</lpage><year>2008</year></element-citation></ref>
<ref id="b13-or-31-04-1961"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voortman</surname><given-names>J</given-names></name><name><surname>Goto</surname><given-names>A</given-names></name><name><surname>Mendiboure</surname><given-names>J</given-names></name><etal/></person-group><article-title>MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma</article-title><source>Cancer Res</source><volume>70</volume><fpage>8288</fpage><lpage>8298</lpage><year>2010</year></element-citation></ref>
<ref id="b14-or-31-04-1961"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer</article-title><source>J Clin Oncol</source><volume>28</volume><fpage>1721</fpage><lpage>1726</lpage><year>2010</year></element-citation></ref>
<ref id="b15-or-31-04-1961"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markou</surname><given-names>A</given-names></name><name><surname>Sourvinou</surname><given-names>I</given-names></name><name><surname>Vorkas</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Clinical evaluation of microRNA expression profiling in non small cell lung cancer</article-title><source>Lung Cancer</source><volume>81</volume><fpage>388</fpage><lpage>396</lpage><year>2013</year></element-citation></ref>
<ref id="b16-or-31-04-1961"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinci</surname><given-names>S</given-names></name><name><surname>Gelmini</surname><given-names>S</given-names></name><name><surname>Pratesi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Genetic variants in <italic>miR-146a</italic>, <italic>miR-149</italic>, <italic>miR-196a2</italic>, <italic>miR-499</italic> and their influence on relative expression in lung cancers</article-title><source>Clin Chem Lab Med</source><volume>49</volume><fpage>2073</fpage><lpage>2080</lpage><year>2011</year></element-citation></ref>
<ref id="b17-or-31-04-1961"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroh</surname><given-names>EM</given-names></name><name><surname>Parkin</surname><given-names>RK</given-names></name><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Tewari</surname><given-names>M</given-names></name></person-group><article-title>Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)</article-title><source>Methods</source><volume>50</volume><fpage>298</fpage><lpage>301</lpage><year>2010</year></element-citation></ref>
<ref id="b18-or-31-04-1961"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>&#x02212;&#x00394;&#x00394;</sup><italic><sup>C</sup></italic><sup>T</sup> method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year></element-citation></ref>
<ref id="b19-or-31-04-1961"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltier</surname><given-names>HJ</given-names></name><name><surname>Latham</surname><given-names>GJ</given-names></name></person-group><article-title>Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues</article-title><source>RNA</source><volume>14</volume><fpage>844</fpage><lpage>852</lpage><year>2008</year></element-citation></ref>
<ref id="b20-or-31-04-1961"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruopp</surname><given-names>MD</given-names></name><name><surname>Perkins</surname><given-names>NJ</given-names></name><name><surname>Whitcomb</surname><given-names>BW</given-names></name><name><surname>Schisterman</surname><given-names>EF</given-names></name></person-group><article-title>Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection</article-title><source>Biom J</source><volume>50</volume><fpage>419</fpage><lpage>430</lpage><year>2008</year></element-citation></ref>
<ref id="b21-or-31-04-1961"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanaihara</surname><given-names>N</given-names></name><name><surname>Caplen</surname><given-names>N</given-names></name><name><surname>Bowman</surname><given-names>E</given-names></name><etal/></person-group><article-title>Unique microRNA molecular profiles in lung cancer diagnosis and prognosis</article-title><source>Cancer Cell</source><volume>9</volume><fpage>189</fpage><lpage>198</lpage><year>2006</year></element-citation></ref>
<ref id="b22-or-31-04-1961"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>GC</given-names></name><etal/></person-group><article-title>MicroRNA signature predicts survival and relapse in lung cancer</article-title><source>Cancer Cell</source><volume>13</volume><fpage>48</fpage><lpage>57</lpage><year>2008</year></element-citation></ref>
<ref id="b23-or-31-04-1961"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takamizawa</surname><given-names>J</given-names></name><name><surname>Konishi</surname><given-names>H</given-names></name><name><surname>Yanagisawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Reduced expression of the <italic>let-7</italic> microRNAs in human lung cancers in association with shortened postoperative survival</article-title><source>Cancer Res</source><volume>64</volume><fpage>3753</fpage><lpage>3756</lpage><year>2004</year></element-citation></ref>
<ref id="b24-or-31-04-1961"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrie</surname><given-names>CH</given-names></name><name><surname>Gal</surname><given-names>S</given-names></name><name><surname>Dunlop</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma</article-title><source>Br J Haematol</source><volume>141</volume><fpage>672</fpage><lpage>675</lpage><year>2008</year></element-citation></ref>
<ref id="b25-or-31-04-1961"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeri</surname><given-names>M</given-names></name><name><surname>Verri</surname><given-names>C</given-names></name><name><surname>Conte</surname><given-names>D</given-names></name><etal/></person-group><article-title>MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer</article-title><source>Proc Natl Acad Sci USA</source><volume>108</volume><fpage>3713</fpage><lpage>3718</lpage><year>2011</year></element-citation></ref>
<ref id="b26-or-31-04-1961"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GK</given-names></name><name><surname>Zhu</surname><given-names>JQ</given-names></name><name><surname>Zhang</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans</article-title><source>Eur Heart J</source><volume>31</volume><fpage>659</fpage><lpage>666</lpage><year>2010</year></element-citation></ref>
<ref id="b27-or-31-04-1961"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>A</given-names></name><name><surname>Natanek</surname><given-names>SA</given-names></name><name><surname>Lewis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased skeletal muscle-specific microRNA in the blood of patients with COPD</article-title><source>Thorax</source><volume>68</volume><fpage>1140</fpage><lpage>1149</lpage><year>2013</year></element-citation></ref>
<ref id="b28-or-31-04-1961"><label>28</label><element-citation publication-type="journal"><collab>National Lung Screening Trial Research Team</collab><person-group person-group-type="author"><name><surname>Aberle</surname><given-names>DR</given-names></name><name><surname>Adams</surname><given-names>AM</given-names></name><name><surname>Berg</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Reduced lung-cancer mortality with low-dose computed tomographic screening</article-title><source>N Engl J Med</source><volume>365</volume><fpage>395</fpage><lpage>409</lpage><year>2011</year></element-citation></ref>
<ref id="b29-or-31-04-1961"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Infante</surname><given-names>M</given-names></name><name><surname>Cavuto</surname><given-names>S</given-names></name><name><surname>Lutman</surname><given-names>FR</given-names></name><etal/></person-group><article-title>A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial</article-title><source>Am J Respir Crit Care Med</source><volume>180</volume><fpage>445</fpage><lpage>453</lpage><year>2009</year></element-citation></ref>
<ref id="b30-or-31-04-1961"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Todd</surname><given-names>NW</given-names></name><etal/></person-group><article-title>Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers</article-title><source>BMC Cancer</source><volume>11</volume><fpage>374</fpage><year>2011</year></element-citation></ref>
<ref id="b31-or-31-04-1961"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzoli</surname><given-names>R</given-names></name><name><surname>Buttitta</surname><given-names>F</given-names></name><name><surname>Di Nicola</surname><given-names>M</given-names></name><etal/></person-group><article-title>microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer</article-title><source>J Thorac Oncol</source><volume>8</volume><fpage>1156</fpage><lpage>1162</lpage><year>2013</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-31-04-1961" position="float">
<label>Figure 1</label>
<caption>
<p>Analysis of miR-499 expression in NSCLC patients and normal controls (N). (A) Box plots of serum levels of miR-499 in patients with stage I (n&#x0003D;20) and stage IV (n&#x0003D;20) NSCLC. (B) Box plots are shown for serum levels of miR-499 from N subjects (n&#x0003D;12) and NSCLC patients (n&#x0003D;12). (C) Box plots are shown for miR-499 levels in primary tumor tissues (NSCLC, n&#x0003D;12) and the adjacent normal tissues (n&#x0003D;12). Expression levels of miR-499 (log 10 scale at y-axis) were normalized to cel-miR-39 and miR-16 expression in sera and tissue. Boxes represent interquartile range, and the horizontal line across each box indicates median value. Mann-Whitney U test was used to determine statistical significance. <sup>&#x0002A;</sup>P&lt;0.001. NSCLC, non-small cell lung cancer.</p></caption>
<graphic xlink:href="OR-31-04-1961-g00.gif"/></fig>
<fig id="f2-or-31-04-1961" position="float">
<label>Figure 2</label>
<caption>
<p>(A) miR-499 expression levels in serum samples. Box plots represent serum miR-499 levels in healthy control subjects (n&#x0003D;54) and different tumor node metastasis (TNM) stages (I, II, III and IV) of NSCLC (n&#x0003D;514). The y-axis (log 10 scale) represents relative expression of miR-499 normalized to cel-miR-39. Horizontal line indicates median value. Mann-Whitney U and Kruskal-Wallis tests were used to determine statistical significance. <sup>&#x0002A;</sup>P&lt;0.001. (B) Receiver operating characteristics (ROC) curve analysis using serum miR-499 for differentiating NSCLC patients from normal control (N) subjects. Serum miR-499 yielded an area under the curve (AUC) value of 0.906 &#x0005B;95&#x00025; confidence interval (CI)&#x0003D;0.879 to 0.929&#x0005D;, with 73.7&#x00025; sensitivity and 92.7&#x00025; specificity in differentiating NSCLC from normal control subjects. NSCLC, non-small cell lung cancer.</p></caption>
<graphic xlink:href="OR-31-04-1961-g01.gif"/></fig>
<fig id="f3-or-31-04-1961" position="float">
<label>Figure 3</label>
<caption>
<p>Kaplan-Meier survival curves of NSCLC patients subdivided by miR-499 levels in serum and matched primary tumors from NSCLC patients. Overall survival rates of patients with (A) stage I&#x02013;IV, (B) stage I&#x02013;II and (C) stage III&#x02013;IV NSCLC with low serum miR-200c levels were significantly lower than those with high miR-499 expression (stage I&#x02013;IV, P&#x0003D;0.005; stage I&#x02013;II, P&#x0003D;0.0012; stage III&#x02013;IV, P&lt;0.001, log-rank test). (D) However, miR-499 levels in tissues were not significantly associated with survival in NSCLC patients (P&#x0003D;0.3139, log-rank test). The optimal miRNA expression cut-off threshold values were deduced from the ROC curves with Youden&#x02019;s index. NSCLC, non-small cell lung cancer.</p></caption>
<graphic xlink:href="OR-31-04-1961-g02.gif"/></fig>
<table-wrap id="tI-or-31-04-1961" position="float">
<label>Table I</label>
<caption>
<p>Association between miR-499 expression in serum and tissue specimens from NSCLC patients and various clinicopathological characteristics.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom"/>
<th colspan="3" align="center" valign="bottom">Serum miR-499 (n&#x0003D;514)</th>
<th colspan="3" align="center" valign="bottom">Tissue miR-499 (n&#x0003D;136)</th></tr>
<tr>
<th align="left" valign="bottom"/>
<th colspan="3" align="left" valign="bottom">
<hr/></th>
<th colspan="3" align="left" valign="bottom">
<hr/></th></tr>
<tr>
<th align="left" valign="bottom">Factors</th>
<th align="center" valign="bottom">High (n&#x0003D;257)</th>
<th align="center" valign="bottom">Low (n&#x0003D;257)</th>
<th align="center" valign="bottom">P-value</th>
<th align="center" valign="bottom">High (n&#x0003D;68)</th>
<th align="center" valign="bottom">Low (n&#x0003D;68)</th>
<th align="center" valign="bottom">P-value</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Age (years)</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="center" valign="top">0.28</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="left" valign="top">0.36</td></tr>
<tr>
<td align="left" valign="top">&#x02003;&#x02264;65</td>
<td align="right" valign="top">111</td>
<td align="right" valign="top">98</td>
<td align="center" valign="top"/>
<td align="right" valign="top">20</td>
<td align="right" valign="top">26</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;&gt;65</td>
<td align="right" valign="top">146</td>
<td align="right" valign="top">159</td>
<td align="center" valign="top"/>
<td align="right" valign="top">48</td>
<td align="right" valign="top">42</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">Gender</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="center" valign="top">0.79</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="left" valign="top">0.17</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Male</td>
<td align="right" valign="top">133</td>
<td align="right" valign="top">137</td>
<td align="center" valign="top"/>
<td align="right" valign="top">39</td>
<td align="right" valign="top">30</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;Female</td>
<td align="right" valign="top">124</td>
<td align="right" valign="top">120</td>
<td align="center" valign="top"/>
<td align="right" valign="top">29</td>
<td align="right" valign="top">38</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">Smoking status</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="center" valign="top">0.36</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="left" valign="top">0.39</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Non-smoker</td>
<td align="right" valign="top">105</td>
<td align="right" valign="top">94</td>
<td align="center" valign="top"/>
<td align="right" valign="top">34</td>
<td align="right" valign="top">40</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;Ever-smoker</td>
<td align="right" valign="top">152</td>
<td align="right" valign="top">163</td>
<td align="center" valign="top"/>
<td align="right" valign="top">34</td>
<td align="right" valign="top">28</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">Stage</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="center" valign="top">0.28</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="left" valign="top">0.22</td></tr>
<tr>
<td align="left" valign="top">&#x02003;I</td>
<td align="right" valign="top">34</td>
<td align="right" valign="top">26</td>
<td align="center" valign="top"/>
<td align="right" valign="top">28</td>
<td align="right" valign="top">22</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;II</td>
<td align="right" valign="top">57</td>
<td align="right" valign="top">45</td>
<td align="center" valign="top"/>
<td align="right" valign="top">35</td>
<td align="right" valign="top">44</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;III</td>
<td align="right" valign="top">46</td>
<td align="right" valign="top">56</td>
<td align="center" valign="top"/>
<td align="right" valign="top">5</td>
<td align="right" valign="top">2</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;IV</td>
<td align="right" valign="top">120</td>
<td align="right" valign="top">130</td>
<td align="center" valign="top"/>
<td align="right" valign="top">0</td>
<td align="right" valign="top">0</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">Histologic type</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="center" valign="top">0.81</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="left" valign="top">0.016</td></tr>
<tr>
<td align="left" valign="top">&#x02003;Adenocarcinoma</td>
<td align="right" valign="top">140</td>
<td align="right" valign="top">146</td>
<td align="center" valign="top"/>
<td align="right" valign="top">52</td>
<td align="right" valign="top">40</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;Squamous cell</td>
<td align="right" valign="top">99</td>
<td align="right" valign="top">92</td>
<td align="center" valign="top"/>
<td align="right" valign="top">14</td>
<td align="right" valign="top">28</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;Others</td>
<td align="right" valign="top">18</td>
<td align="right" valign="top">19</td>
<td align="center" valign="top"/>
<td align="right" valign="top">2</td>
<td align="right" valign="top">0</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">Surgical operation</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="center" valign="top">0.02</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="left" valign="top">0.93</td></tr>
<tr>
<td align="left" valign="top">&#x02003;No</td>
<td align="right" valign="top">172</td>
<td align="right" valign="top">196</td>
<td align="center" valign="top"/>
<td align="right" valign="top">0</td>
<td align="right" valign="top">0</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;Yes</td>
<td align="right" valign="top">85</td>
<td align="right" valign="top">61</td>
<td align="center" valign="top"/>
<td align="right" valign="top">68</td>
<td align="right" valign="top">68</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">Chemotherapy or radiotherapy</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="center" valign="top">0.08</td>
<td align="right" valign="top"/>
<td align="right" valign="top"/>
<td align="left" valign="top">0.12</td></tr>
<tr>
<td align="left" valign="top">&#x02003;No</td>
<td align="right" valign="top">55</td>
<td align="right" valign="top">39</td>
<td align="center" valign="top"/>
<td align="right" valign="top">5</td>
<td align="right" valign="top">12</td>
<td align="left" valign="top"/></tr>
<tr>
<td align="left" valign="top">&#x02003;Yes</td>
<td align="right" valign="top">202</td>
<td align="right" valign="top">218</td>
<td align="center" valign="top"/>
<td align="right" valign="top">63</td>
<td align="right" valign="top">56</td>
<td align="left" valign="top"/></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-or-31-04-1961">
<p>NSCLC, non-small cell lung cancer.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tII-or-31-04-1961" position="float">
<label>Table II</label>
<caption>
<p>Univariate and multivariate analyses for prognostic factors in patients with NSCLC.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom"/>
<th colspan="3" align="center" valign="bottom">Univariate</th>
<th colspan="3" align="center" valign="bottom">Multivariate</th></tr>
<tr>
<th align="left" valign="bottom"/>
<th colspan="3" align="left" valign="bottom">
<hr/></th>
<th colspan="3" align="left" valign="bottom">
<hr/></th></tr>
<tr>
<th align="left" valign="bottom">Variables</th>
<th align="center" valign="bottom">HR</th>
<th align="center" valign="bottom">95&#x00025; CI</th>
<th align="center" valign="bottom">P-value</th>
<th align="center" valign="bottom">HR</th>
<th align="center" valign="bottom">95&#x00025; CI</th>
<th align="center" valign="bottom">P-value</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Age, years (&gt;65 vs. &#x02264;65)</td>
<td align="center" valign="top">0.84</td>
<td align="center" valign="top">0.61&#x02013;1.16</td>
<td align="right" valign="top">0.2855</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/></tr>
<tr>
<td align="left" valign="top">Gender (female vs. male)</td>
<td align="center" valign="top">0.98</td>
<td align="center" valign="top">0.80&#x02013;1.20</td>
<td align="right" valign="top">0.8212</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">Histology (squamous vs. non-squamous)</td>
<td align="center" valign="top">0.91</td>
<td align="center" valign="top">0.74&#x02013;1.12</td>
<td align="right" valign="top">0.37</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">Pathological T (T3/4 vs. T1/2)</td>
<td align="center" valign="top">2.39</td>
<td align="center" valign="top">1.94&#x02013;2.94</td>
<td align="right" valign="top">&lt;0.0001</td>
<td align="center" valign="top">1.45</td>
<td align="center" valign="top">1.10&#x02013;1.89</td>
<td align="center" valign="top">0.0077</td></tr>
<tr>
<td align="left" valign="top">Lymph node metastasis (N1&#x02013;3 vs. N0)</td>
<td align="center" valign="top">1.80</td>
<td align="center" valign="top">1.46&#x02013;2.20</td>
<td align="right" valign="top">&lt;0.0001</td>
<td align="center" valign="top">1.21</td>
<td align="center" valign="top">0.95&#x02013;1.54</td>
<td align="center" valign="top">0.1333</td></tr>
<tr>
<td align="left" valign="top">Distant metastasis (M1 vs. M0)</td>
<td align="center" valign="top">2.67</td>
<td align="center" valign="top">2.14&#x02013;3.32</td>
<td align="right" valign="top">&lt;0.0001</td>
<td align="center" valign="top">1.68</td>
<td align="center" valign="top">1.32&#x02013;2.14</td>
<td align="center" valign="top">&lt;0.0001</td></tr>
<tr>
<td align="left" valign="top">TNM stage (III/IV vs. I/II)</td>
<td align="center" valign="top">3.57</td>
<td align="center" valign="top">2.91&#x02013;4.40</td>
<td align="right" valign="top">&lt;0.0001</td>
<td align="center" valign="top">21.63</td>
<td align="center" valign="top">2.98&#x02013;156.85</td>
<td align="center" valign="top">0.0025</td></tr>
<tr>
<td align="left" valign="top">Chemotherapy or radiotherapy (no vs. yes)</td>
<td align="center" valign="top">1.49</td>
<td align="center" valign="top">0.94&#x02013;2.38</td>
<td align="right" valign="top">0.0928</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">miR-499 in serum (low vs. high)</td>
<td align="center" valign="top">1.42</td>
<td align="center" valign="top">1.16&#x02013;1.75</td>
<td align="right" valign="top">0.0005</td>
<td align="center" valign="top">1.63</td>
<td align="center" valign="top">1.33&#x02013;2.00</td>
<td align="center" valign="top">&lt;0.0001</td></tr>
<tr>
<td align="left" valign="top">miR-499 in tumor (low vs. high)</td>
<td align="center" valign="top">1.31</td>
<td align="center" valign="top">0.77&#x02013;2.21</td>
<td align="right" valign="top">0.3139</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn2-or-31-04-1961">
<p>HR, hazard ratio; CI, confidence interval. Cut-off values of miR-499 in tissue and serum are derived from receiver operating characteristic curve with Youden&#x02019;s index. NSCLC, non-small cell lung cancer.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tIII-or-31-04-1961" position="float">
<label>Table III</label>
<caption>
<p>Univariate and multivariate analyses for predictive factors of recurrence in patients with stage I&#x02013;II NSCLC.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom"/>
<th colspan="3" align="center" valign="bottom">Univariate</th>
<th colspan="3" align="center" valign="bottom">Multivariate</th></tr>
<tr>
<th align="left" valign="bottom"/>
<th colspan="3" align="left" valign="bottom">
<hr/></th>
<th colspan="3" align="left" valign="bottom">
<hr/></th></tr>
<tr>
<th align="left" valign="bottom">Variables</th>
<th align="center" valign="bottom">HR</th>
<th align="center" valign="bottom">95&#x00025; CI</th>
<th align="center" valign="bottom">P-value</th>
<th align="center" valign="bottom">HR</th>
<th align="center" valign="bottom">95&#x00025; CI</th>
<th align="center" valign="bottom">P-value</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Age, years (&gt;65 vs. &#x02264;65)</td>
<td align="center" valign="top">1.11</td>
<td align="center" valign="top">0.62&#x02013;1.97</td>
<td align="left" valign="top">0.7346</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
<td align="center" valign="top"/></tr>
<tr>
<td align="left" valign="top">Gender (female vs. male)</td>
<td align="center" valign="top">0.66</td>
<td align="center" valign="top">0.31&#x02013;1.42</td>
<td align="left" valign="top">0.29</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">Pathological T (T2/3 vs. T1)</td>
<td align="center" valign="top">2.22</td>
<td align="center" valign="top">0.62&#x02013;8.01</td>
<td align="left" valign="top">0.22</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">Lymph node metastasis (N1 vs. N0)</td>
<td align="center" valign="top">1.24</td>
<td align="center" valign="top">0.23&#x02013;6.69</td>
<td align="left" valign="top">0.8024</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">TNM stage (II vs. I)</td>
<td align="center" valign="top">2.54</td>
<td align="center" valign="top">1.13&#x02013;5.71</td>
<td align="left" valign="top">0.024</td>
<td align="center" valign="top">2.76</td>
<td align="center" valign="top">1.32&#x02013;5.77</td>
<td align="center" valign="top">0.007</td></tr>
<tr>
<td align="left" valign="top">Chemotherapy or radiotherapy (no vs. yes)</td>
<td align="center" valign="top">1.39</td>
<td align="center" valign="top">1.06&#x02013;1.81</td>
<td align="left" valign="top">0.0158</td>
<td align="center" valign="top">1.61</td>
<td align="center" valign="top">1.15&#x02013;2.26</td>
<td align="center" valign="top">0.0057</td></tr>
<tr>
<td align="left" valign="top">miR-499 in serum (low vs. high)</td>
<td align="center" valign="top">3.03</td>
<td align="center" valign="top">1.11&#x02013;8.27</td>
<td align="left" valign="top">0.0304</td>
<td align="center" valign="top">1.96</td>
<td align="center" valign="top">1.03&#x02013;3.73</td>
<td align="center" valign="top">0.04</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn3-or-31-04-1961">
<p>HR, hazard ratio; CI, confidence interval. Cut-off value of serum miR-499 is derived from receiver operating characteristic curve with Youden&#x02019;s index. NSCLC, non-small cell lung cancer.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
